T. Rowe Price Associates’s EyePoint Pharmaceuticals EYPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $788K | Sell |
83,709
-1,270,305
| -94% | -$12M | ﹤0.01% | 2089 |
|
|
2025
Q1 | $7.34M | Sell |
1,354,014
-790,733
| -37% | -$4.29M | ﹤0.01% | 1169 |
|
|
2024
Q4 | $16M | Sell |
2,144,747
-347,466
| -14% | -$2.59M | ﹤0.01% | 1036 |
|
|
2024
Q3 | $19.9M | Sell |
2,492,213
-10,158
| -0.4% | -$81.2K | ﹤0.01% | 993 |
|
|
2024
Q2 | $21.8M | Buy |
2,502,371
+36,556
| +1% | +$318K | ﹤0.01% | 945 |
|
|
2024
Q1 | $51M | Sell |
2,465,815
-56,889
| -2% | -$1.18M | 0.01% | 725 |
|
|
2023
Q4 | $58.3M | Buy |
2,522,704
+1,148,358
| +84% | +$26.5M | 0.01% | 659 |
|
|
2023
Q3 | $11M | Buy |
+1,374,346
| New | +$11M | ﹤0.01% | 1060 |
|